Exclusive Drug Patent Licensing Deals Face New Scrutiny By FTC/DOJ
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission finalized a proposed rule that requires pharma companies to report certain transactions transferring exclusive patent rights; PhRMA says annual costs will go far beyond FTC’s $1.2 million estimate.
You may also be interested in...
Patent Licensing Deals Could Be More Costly Under FTC Proposed Rules
Federal Trade Commission is proposing to amend pre-merger notification rules related to the transfer of exclusive patent rights in the pharmaceutical industry; the change would require reporting transactions in which the licensor retains exclusive manufacturing rights.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.